251 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards https://www.fool.com/investing/2017/05/09/i-still-cant-believe-gilead-sciences-inc-spent-147.aspx?source=iedfolrf0000001 May 09, 2017 - Gilead's M&A targets may be limited because of its sizable shareholder rewards program.
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals http://www.zacks.com/stock/news/253076/zackscom-featured-highlights-covanta-holding-etsy-ptc-incyte-and-vertex-pharmaceuticals?cid=CS-ZC-FT-253076 Mar 16, 2017 - Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
Why Snyder's-Lance, Incyte, and Tenet Healthcare Slumped Today https://www.fool.com/investing/2017/04/17/why-snyders-lance-incyte-and-tenet-healthcare-slum.aspx?source=iedfolrf0000001 Apr 17, 2017 - Despite a climbing market, these stocks fell. Find out why.
What Happened in the Stock Market Today https://www.fool.com/investing/2017/04/17/what-happened-in-the-stock-market-today.aspx?source=iedfolrf0000001 Apr 18, 2017 - Drugmakers get denied, Chipotle continues gains, and earnings season gets under way. Investors have remained optimistic ahead of what could be a tumultuous week.
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August https://www.fool.com/investing/2017/09/05/the-key-reason-incyte-corporation-added-850-millio.aspx?source=iedfolrf0000001 Sep 05, 2017 - An update on bariticinib's review timeline has Wall Street rightly excited.
3 Small-Cap Biotech Stocks to Buy This Fall https://www.fool.com/investing/2017/09/21/3-small-cap-biotech-stocks-to-buy-this-fall.aspx?source=iedfolrf0000001 Sep 21, 2017 - Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.
Should Gilead Sciences Acquire NewLink Genetics? https://www.fool.com/investing/2017/04/21/gilead-sciences-should-acquire-newlink-genetics.aspx?source=iedfolrf0000001 Apr 21, 2017 - NewLink Genetics intriguing IDO-inhibitors could make it a target of Gilead Sciences.
This $26 Billion Company Is the Market's Most Overpriced Biotech Stock https://www.fool.com/investing/2017/04/20/this-26-billion-company-is-the-markets-most-overpr.aspx?source=iedfolrf0000001 Apr 20, 2017 - Nearly 90% of this biotech's sales could be at risk within the next two years.
Why Incyte Corporation Stock Is Plunging Today https://www.fool.com/investing/2017/04/17/why-incyte-corporation-stock-is-plunging-today.aspx?source=iedfolrf0000001 Apr 17, 2017 - Shares of Incyte and Eli Lilly are reeling following the FDA's rejection of their once-daily rheumatoid arthritis pill.
Incyte & Hengrui to Develop Anti-PD-1 Monoclonal Antibody http://www.zacks.com/stock/news/188899/incyte-hengrui-to-develop-anti-pd-1-monoclonal-antibody?cid=CS-ZC-FT-188899 Sep 03, 2015 - Incyte (INCY) signs an agreement with Hengrui to develop and commercialize an anti-PD-1 monoclonal antibody, SHR-1210.

Pages: 1234567...26

<Page 2>